Neolizumab for pruritus

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Nov 2026: Trial registered, NCT07926867

The trials

NCT07926867: A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa

State
Not started
Phase
Phase 2 and Phase 3
People
15 planned
Started
31 Dec 2026
Primary completion
31 Dec 2027
Arms
Nemolizumab will be administered as a 60 mg loading dose (two 30 mg injections) at Day 0, followed b
Results
None posted
  1. 9 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.